NUCALA HAS A WELL-ESTABLISHED SAFETY PROFILE WITH LONG-TERM DATA IN SEA

A total of 1327 patients ≥12 years of age with severe asthma were evaluated in 3 randomized, placebo-controlled, multicenter trials of 24 to 52 weeks’ duration: Trial 1,* Trial 2, and Trial 3. Approximately 2% of patients receiving NUCALA withdrew from these clinical trials due to adverse events vs 3% of patients receiving placebo.

*Trial 1: 52-week dose-ranging exacerbation study.

NUCALA safety data in severe eosinophilic asthma (SEA)

ADVERSE REACTIONS (SIDE EFFECTS) ≥3% (AND MORE COMMON THAN PLACEBO) IN THE FIRST 24 WEEKS OF TRIAL 2 AND TRIAL 3

NUCALA safety data in severe eosinophilic asthma (SEA) NUCALA safety data in severe eosinophilic asthma (SEA)

Patients aged 6 to 11 years: Adverse reaction profile similar to trials in patients aged ≥12 years.

 

Serious adverse events (SAE): One SAE occurred in >1 patient and more frequently with NUCALA than placebo: herpes zoster (2 vs 0 patients).

 

Systemic reactions: In the 3 clinical trials, NUCALA 3% and placebo 5%.

  • Manifestations included rash, flushing, pruritus, headache, and myalgia. A majority were experienced on the day of dosing.

 

Immunogenicity: Across clinical trials in patients aged ≥6 years receiving NUCALA, 6% developed anti-mepolizumab antibodies and 1 patient had neutralizing antibodies detected. The clinical relevance of anti-mepolizumab antibodies is not known.

 

NUCALA was also evaluated in a 4.5-year open-label safety and efficacy study.1

See long-term data

NUCALA is the only biologic for SEA with an open-label study up to 6.4 years2

There were no unexpected safety findings in this long-term access study of patients aged ≥6 years.*

OPEN-LABEL, LONG-TERM ACCESS STUDY: SAFETY RESULTS (%)

Open-label, long-term access study: safety results (%) Open-label, long-term access study: safety results (%)

Median exposure to NUCALA: 15.5 months (1-77 months)

 

Serious AEs

  • Reported in >1% of patients: worsening of asthma (3%)

 

Non-serious AEs

  • Reported in ≥10% of patients: worsening of asthma (30%), lower respiratory tract infection (11%), and headache (10%)

*Add-on NUCALA every 4 weeks 100 mg SC for patients aged ≥12 years; 40 mg SC for patients aged 6-11 years.

†Safety population included patients who received ≥1 NUCALA dose.

‡As determined by the investigator.

§Non-serious AE population included patients who received ≥1 NUCALA dose and were required per protocol to report non-serious AEs (select non-US countries and pediatric study).

See 6.4-year, open-label
study design

AE=adverse event; SC=subcutaneous.

BLOOD EOSINOPHIL UNIT CONVERSION CALCULATOR

In asthma, an elevated EOS count is a sign that your patient may have eosinophilic asthma. Obtain an absolute eosinophil count in cells/µL from lab results to help decide if NUCALA is right for your patient.

GET EOSINOPHIL COUNTS

GATEWAY TO NUCALA ENROLLMENT FORM

For biologic coordinators and other HCPs who help patients manage their NUCALA injection therapy: get resources right now to help them start and stay on NUCALA.

GO TO ACCESS & SUPPORT

EXPLORE LONG-TERM DATA IN 4.5-YEAR OPEN-LABEL STUDY

In patients with severe eosinophilic asthma (SEA), NUCALA was evaluated in a 4.5-year open-label safety and efficacy study.1,2

GO TO LONG-TERM DATA